Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Great News! Nothing to hold us back now. Hopefully this will fly on Monday!
This is excellent news. They settled for about 1/3 of the charge they took.
Wait no, I read that wrong!!
It’s only $102 million??
Https://otp.tools.investis.com/clients/uk/indivior2/rns/regulatory-story.aspx?cid=971&newsid=1692361
Looks like it’s the $290 million charge they originally reserved against.
Stock is still yawning here. I wonder what the catalyst is here. Hopefully the NASDAQ listing drives some buying.
Jefferies raises Indivior price target to 2,330 (2,115) pence - 'buy'.
Plenty of upside with strong trading reflected in recent trading update.
NASDAQ dealings begin June 12th.
FDA approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl.
Mythyaar, thanks for your thoughts. I think it’s safe to say, we have a clean runway overall looking ahead. The NASDAQ uplisting should be a catalyst, as it brings in new investors.
One follow up thought… Indivior having 2% market share target for the $1.5 billion Sublocade revenue target. What are the other big opioid drugs? If you only have 2% market share, can’t someone bigger basically outcompete you? I guess I am trying to get a better understanding of the different drugs in the opioid market.
Idkmybffjill. Thanks for the updates.
1. Camurus - is it that big of a deal? The market is growing, there are no signs of the opioid crisis abating. Will Camurus really be eating into Indivior's market share, which is still only scratching the surface at 2%? Even if Indivior maintained the 2% of a growing market, they'd still hit over £1 billion turnover, particularly with the OPVEE add on from Q4 onwards (likely £150 mill p.a thereafter).
2. good news about the Nasdaq date now made known.
3. Litigation - seems to be a tactic by the Indivior legal advisors to get it thrown out. Standard procedure I don't doubt. However, it doesn't seem that the mediation behind the scenes (and any potential settlement) is that near if they're employing such a tactic. Patience wearing thin?
Copying pasting from another investor site I’m a member of:
“In the last 2 days-
Bad news:
- Brixadi approved and will compete directly with Sublocade
- https://www.camurus.com/media/press-releases/2023/camurus-announces-fda-approval-of-brixadi-for-the-treatment-of-moderate-to-severe-opioid-use-disorder/
- https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder?utm_medium=email&utm_source=govdelivery
- Any color on Braeburn's current financial position and ability to launch? Braeburn owes $35M on approval here.
Good news
- OPNT003 (OPVEE) approved
- We owned/followed OPNT closely. I think this sells well north of the $150M estimate at the time of acquisition. Narcan did $430M in 2021 before it went generic and OPVEE has a chance to be the one first responders carry.
- Indivior Nasdaq listing starts trading June 12”
Hillel West sells 110,000 shares at GBP15.70 each on Friday last week. Total aggregate value is GBP1.7 million.
Indivior Wants Class Tossed From Suboxone Antitrust Case
By Piper Hudspeth Blackburn
Law360 (May 11, 2023, 6:05 PM EDT) -- Indivior urged a Pennsylvania federal court on Thursday to dismiss a class of end payors from a case accusing the company of monopolizing the market for the opioid addiction treatment Suboxone, arguing the end payors have never demonstrated how they "suffered any harm" from the alleged violations.
In a motion to dismiss, the Virginia-based pharmaceutical company also asked U.S. District Judge Mitchell Goldberg to decertify the end-payor class if he didn't dismiss the suit outright. According to Indivior, certification should be reconsidered because it occurred before the Third Circuit's 2021 ruling in Russell v. Education Commission for Foreign Medical Graduates, "which changed the law on class certification."
In that case, the court held that in cases where a class is certified to collectively address only some issues before individually handling other issues, they have to satisfy the typical rules of civil procedure and consider a list of nine factors the Third Circuit had laid out in 2011 in Gates v. Rohm & Haas Co.
"This court must revisit its class certification decision prior to trial; because that decision predated Russell, it did not conduct Russell's required analysis," the motion stated.
The plaintiffs, which consist of direct purchasers, end payors and a group of state attorneys general, have claimed that Indivior, formerly known as Reckitt Benckiser Inc., attempted to maintain its hold on the Suboxone market through a tactic known as a "product hop."
According to the plaintiffs, the company moved to an under-the-tongue, dissolvable "film" form of Suboxone after protection from generics for its Suboxone tablets expired, in order to continue their market exclusivity.
Judge Goldberg certified the class of end payors in 2019, though only to decide whether there was anticompetitive conduct, meaning members of that group would have to bring individual cases if a jury finds the conduct occurred. The ruling, which also certified a class of direct purchasers, was later affirmed by the Third Circuit.
A trial is slated to begin Sept. 18, just months past what the state enforcers and others asked for in November.
Judge Goldberg rejected a bid from Indivior for an early victory in August, finding that the suit's claims rest on issues of fact that belong before a jury.
On Thursday, Indivior insisted that because the end payors haven't shown how they have suffered from the alleged scheme through "specific facts," like the amount of money they otherwise overpaid, they can't demonstrate Article III standing at summary judgment.
"EPPs have not demonstrated that each class member sustained concrete harm — and a great many are plainly unharmed," the company said.
Https://www.law360.com/articles/1606950/indivior-wants-class-tossed-from-suboxone-antitrust-case
Yeah guess I did lol. Thankfully, the business continues to grow nicely…
Maybe you spoke too soon!
And equally relevant is INDV agreement with Aelis Farma re AEF0117:
AEF0117, which targets disorders due to excessive cannabis use (addiction and psychosis), has shown indications of efficacy in a phase 2a clinical trial and entered a phase 2b clinical trial in the United States in Q2 2022. Aelis Farma has an exclusive option-license agreement with Indivior PLC, a leading pharmaceutical company in the treatment of addiction, for the development and commercialization of AEF0117 for disorders due to excessive cannabis use. As part of this agreement, Aelis Farma has already received $30 million (option payment). If Indivior exercises the license option at the end of the phase 2b, Aelis Farma will receive a $100 million license fee (potentially in 2024) and Indivior will take responsibility for additional development costs. The agreement also includes up to $340 million in additional payments contingent on the achievement of development, regulatory and commercial milestones, as well as royalties on net sales of AEF0117 ranging between 12% and 20%.
Analysts positive aggregate 12m price forecasts for both INDV and AELIS, both higher by 50%+. 4 and 3 analysts covering respectively, all 7 strong buy.
On April 3rd, this user posted:
“Worst company I bought, massive mistake”
“This is a true dog of a share, sell before you get f**ked over. A total ****e case”
On April 5:
“ But this company is too fishy for me.
Big director sales reversing the effect of the 100m buy back.
MS buying in but doing nothing for the sp.
Just a dog of a share so I'm out. Will look to recover losses elsewhere.”
Funny enough, him selling his shares marked the bottom for the stock. Up up and away we go!
Was there another recent investor call? Or are you referring to the one from late last year?
Interesting article (part copied below) in Daily Telegraph covering link between cannabis use & schizophrenia.
INDV's Perseris combats schizophrenia.
"Almost a third of schizophrenia cases in young men triggered by cannabis use
Heavy use of the drug described as ‘a major public health issue’ despite an increasing number of countries embracing legalisation.
Young men with a serious cannabis addiction are at increased risk of developing schizophrenia, a new study suggests.
Experts estimate that nearly one third of cases of schizophrenia in 21 to 30-year-olds were triggered by cannabis use disorder.
Cannabis use disorder is thought to impact around 1 in 200 people, and relates to problematic cannabis use where people cannot control their intake and suffer withdrawal symptoms if they stop taking the drug.
A new study led by Danish researchers analysed the health records of nearly seven million people over 50 years and found a strong link between schizophrenia and serious cannabis addiction.
As many as 30 per cent of cases of schizophrenia among men aged 21 to 30, and 15 per cent of cases in 16 to 49-year-olds, could have been prevented by preventing cannabis addiction, they estimate."
Same as it was last year now, give or take a few pence!
Thanks Cashola. Obviously, the two examples you've given aren't really impacted by time zones. Would be interesting if for example, INDV went on a run (either up or down) on the FTSE and that then continued on the NASDAQ?!
It's different each time/each company. But lots of companies are dual-listed e.g. TUI (Germany) , DALATA (Ireland). From what I've seen, one listing tends to lead the other. The question is where the shares will come from as I can't recall how it's done.
One of the questions on the investors call was how this additional listing was going to impact INDV UK listing and if it was eventually going to replace it. The response was that it wasn't (as far as I understood). Does anyone know what the impact will be of having two listings?
divis from other companies
What divy’s?
Revenue growth continues to be very strong.
Very pleasant "steady as she goes" results. I'll be topping up if it's still under £17 when next month's divis become available.